Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Allievex Corp.

Headquarters: Marblehead, MA, United States of America
Year Founded: N/A
Status: Archived

Historical deals and financings can be found by searching the organization's name in the BCIQ Deals and Financing Modules.

BioCentury | Mar 1, 2024
Product Development

Rare disease spotlight: enzyme replacement therapy for the brain

At least seven companies aim to overcome the challenge of delivering an enzyme across the blood-brain barrier to treat MPS IIIA
BioCentury | Feb 29, 2024
Regulation

Ultrarare inflection point: stakeholders argue for biomarker-based approvals

Reagan-Udall Foundation meeting on biomarkers could change FDA policy on neuronal MPS endpoints, unleash approvals
BioCentury | Nov 13, 2019
Finance

Allievex, backed by Pappas and Novo, scoops up BioMarin ultra-rare disease assets

Why Pappas created Allievex to shepherd an MPS IIIB program and other ultra-orphan assets
BioCentury | Oct 24, 2019
Finance

Allievex, backed by Pappas and Novo, scoops up BioMarin ultra-rare disease assets

Why Pappas created Allievex to shepherd an MPS IIIB program and other ultra-orphan assets
Items per page:
1 - 4 of 4
Help Center
Username
Request a Demo
Request Training
Ask a Question